QUARTERLY ACTIVITIES REPORT & 4C
0
Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021. Our R&D program…
PAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer
New preclinical data from the Garvan Institute of Medical Research has shown that Patrys’ deoxymab antibody PAT-DX1 is able to…
New data shows PAT-DX3 able to cross the blood brain barrier
In an exciting development, Patrys today announced new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross…
Bioshares | June 2021
Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares. The article highlights our Company’s strong…
Stockhead V-Con Biotechs
Patrys is delighted to be participating in the V-Con Biotechs conference this week. Presented by Stockhead, V-Con is an opportunity…
180 Markets Interview
Patrys CEO and MD, Dr James Campbell, was recently interviewed by 180 Markets CEO and Co-Founder, Greg Lowe, to summarise…
Patrys in The Australian
Patrys appears on page 7 of The Australian today as part of a story secured with the newspaper’s Health Editor,…
New Data | PAT-DX1
Patrys is pleased to announce the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating…
Newsletter | June 2021
Patrys is pleased to share its latest Newsletter, published June 2021. Key highlights: Letter from our CEO Media and analyst…
Fierce Biotech | Prof Peter Glazer
Fierce Biotech has reported on another of Professor Peter Glazer’s start-up ventures. Peter also has experience working with our PAT-DX1…